Öppna denna publikation i ny flik eller fönster >>Visa övriga...
2020 (Engelska)Ingår i: Scientific Reports, E-ISSN 2045-2322, Vol. 10, nr 1, artikel-id 8029Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Endomyocardial biopsy is a valuable tool in cardiac diagnostics but is limited by low diagnostic yield and significant complication risks. Meanwhile, recent developments in transcriptomic and proteomic technologies promise a wealth of biological data from minimal tissue samples. To take advantage of the minimal tissue amount needed for molecular analyses, we have developed a sub-millimeter endovascular biopsy device, considerably smaller than current clinical equipment, and devised a low-input RNA-sequencing protocol for analyzing small tissue samples. In in vivo evaluation in swine, 81% of biopsy attempts (n=157) were successful. High quality RNA-sequencing data was generated from 91% of the sequenced cardiac micro-biopsy samples (n=32). Gene expression signatures of samples taken with the novel device were comparable with a conventional device. No major complications were detected either during procedures or during 7 days' follow-up, despite acquiring a relatively large number of biopsies (median 30) in each animal. In conclusion, the novel device coupled with RNA-sequencing provides a feasible method to obtain molecular data from the myocardium. The method is less traumatic and has a higher flexibility compared to conventional methods, enabling safer and more targeted sampling from different parts of the myocardium.
Ort, förlag, år, upplaga, sidor
Springer Nature, 2020
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:kth:diva-281166 (URN)10.1038/s41598-020-64900-w (DOI)000562205900004 ()32415191 (PubMedID)2-s2.0-85084785903 (Scopus ID)
Anmärkning
QC 20201015
2020-10-152020-10-152023-08-09Bibliografiskt granskad